Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Orphan Drugs
  • R&D 100 Awards

Pfizer-BioNTech COVID-19 vaccine 91.3% effective after six months

By Brian Buntz | April 1, 2021

Pfizer-BioNTechThe first COVID-19 vaccine to win emergency use authorization in the U.S. is highly effective for at least six months after the second dose. Developed jointly by Pfizer (NYSE: PFE) and BioNTech (NSDQ: BNTX), the BNT162b2 vaccine  

The durability of COVID-19 vaccines had been something of an open question, although early clinical data suggested that Moderna’s mRNA-1273 COVID-19 vaccine was effective for at least 90 days after the second dose.

Pfizer plans on releasing more data related to the long-term vaccine immunogenicity in the coming weeks.

Pfizer and BioNTech plan on doing two years of follow-up for their Phase 3 vaccine trial.

Earlier this year, the two companies released data indicating that their vaccine also remains effective against a highly-transmissible SARS-CoV-2 variant first identified in South Africa.

Pfizer and BioNTech are also testing the vaccine on adolescents. Recent data suggest that the vaccine is 100% effective in adolescents aged 12 to 15 years old.

The companies are planning to file for full FDA approval of the vaccine as soon as this month. The vaccine would be the first to win that status.

Pfizer and BioNTech also recently announced that they aim to boost annual production of COVID-19 vaccine doses to 2.5 billion doses by the end of the year. Some 1.4 billion doses have already been ordered in purchase agreements.

BioNTech also announced that it is working on lyophilized and ready-to-use liquid formulations of the vaccine. Both would be easier to distribute than the current formulation, which requires ultracold storage. The ready-to-use formulation could be available in the second half of the year.

Tell Us What You Think! Cancel reply

You must be logged in to post a comment.

Related Articles Read More >

Coronavirus vaccine
6 things to know as AstraZeneca and J&J COVID-19 vaccines face safety scrutiny
Johnson & Johnson
Feds halt J&J COVID-19 vaccine due to blood clot concern
Pfizer-BioNTech
Pfizer asks FDA to authorize its COVID-19 vaccine for younger teens
Johnson & Johnson
EMA begins investigation of J&J COVID-19 vaccine’s blood clotting potential 

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup

R&D Twitter

Tweets by @RandDWorld
Drug Discovery and Development
  • Enews Signup
  • Contact Us
  • R&D World
  • Pharmaceutical Processing
  • Drug Delivery Business News

Copyright © 2021 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Orphan Drugs
  • R&D 100 Awards